TY - BOOK AU - Rebelatto, M. AU - Mistry, A. AU - Sabalos, C. AU - Walker, J. AU - Midha, A. AU - Steele, K. PY - 2015 DA - 2015// TI - Development of a PD-L1 Companion Diagnostic Assay for Treatment With MEDI4736 in NSCLC and SCCHN Patients PB - Poster presented at the 51st American Society of Clinical Oncology Annual Meeting CY - Chicago ID - Rebelatto2015 ER - TY - JOUR AU - Rebelatto, M. C. AU - Mistry, A. AU - Sabalos, C. AU - Schechter, N. AU - Walker, J. AU - Midha, A. PY - 2016 DA - 2016// TI - An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B005 DO - 10.1158/2326-6074.CRICIMTEATIAACR15-B005 ID - Rebelatto2016 ER - TY - JOUR AU - Vermorken, J. B. AU - Herbst, R. S. AU - Leon, X. AU - Amellal, N. AU - Baselga, J. PY - 2008 DA - 2008// TI - Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies JO - Cancer VL - 112 UR - https://doi.org/10.1002/cncr.23442 DO - 10.1002/cncr.23442 ID - Vermorken2008 ER - TY - JOUR AU - Shin, D. M. AU - Khuri, F. R. PY - 2013 DA - 2013// TI - Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck JO - Head Neck VL - 35 UR - https://doi.org/10.1002/hed.21910 DO - 10.1002/hed.21910 ID - Shin2013 ER - TY - STD TI - D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(5_Suppl):v116–9. doi:10.1093/annonc/mdq189. ID - ref5 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - STD TI - Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82. doi:10.1200/JCO.2014.59.4358. ID - ref7 ER - TY - JOUR AU - Tarhini, A. A. PY - 2013 DA - 2013// TI - Tremelimumab: a review of development to date in solid tumors JO - Immunotherapy VL - 5 UR - https://doi.org/10.2217/imt.13.9 DO - 10.2217/imt.13.9 ID - Tarhini2013 ER - TY - JOUR AU - Zou, W. AU - Chen, L. PY - 2008 DA - 2008// TI - Inhibitory B7-family molecules in the tumour microenvironment JO - Nat Rev Immunol VL - 8 UR - https://doi.org/10.1038/nri2326 DO - 10.1038/nri2326 ID - Zou2008 ER - TY - STD TI - Food and Drug Administration (FDA). News Release. FDA approves Opdivo to treat advanced form of kidney cancer. 23 November 2015. Last updated 25 November 2015. Last accessed 17 March 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm. UR - http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm ID - ref10 ER - TY - STD TI - European Medicines Agency (EMA). What is Opdivo and what is it used for? Updated 4 March 2016. Last accessed 17 March 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124. UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124 ID - ref11 ER - TY - STD TI - Merck Sharp & Dohme. Highlights of prescribing information: Keytruda. Updated December 2015. Last accessed 11 August 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf. UR - http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf ID - ref12 ER - TY - STD TI - European Medicines Agency (EMA). What is Keytruda and what is it used for. Updated 30 July 2015. Last accessed 16 March 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124. UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124 ID - ref13 ER - TY - STD TI - Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED). PD-L1 IHC 28–8 pharmDx. 9 October 2015. Last accessed 11 January 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150025b.pdf. UR - http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150025b.pdf ID - ref14 ER - TY - STD TI - Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED). PD-L1 IHC 22C3 pharmDx. 2 October 2015. Last accessed 11 January 2016. http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013b.pdf. UR - http://www.accessdata.fda.gov/cdrh_docs/pdf15/p150013b.pdf ID - ref15 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Brown, J. A. AU - Dorfman, D. M. AU - Ma, F. R. AU - Sullivan, E. L. AU - Munoz, O. AU - Wood, C. R. PY - 2003 DA - 2003// TI - Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production JO - J Immunol VL - 170 UR - https://doi.org/10.4049/jimmunol.170.3.1257 DO - 10.4049/jimmunol.170.3.1257 ID - Brown2003 ER - TY - JOUR AU - Lyford-Pike, S. AU - Peng, S. AU - Young, G. D. AU - Taube, J. M. AU - Westra, W. H. AU - Akpeng, B. PY - 2013 DA - 2013// TI - Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-2384 DO - 10.1158/0008-5472.CAN-12-2384 ID - Lyford-Pike2013 ER - TY - JOUR AU - Bellmunt, J. AU - Mullane, S. A. AU - Werner, L. AU - Fay, A. P. AU - Callea, M. AU - Leow, J. J. PY - 2015 DA - 2015// TI - Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv009 DO - 10.1093/annonc/mdv009 ID - Bellmunt2015 ER - TY - STD TI - Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89(2):181–8. doi:10.1016/j.lungcan.2015.05.007. ID - ref20 ER - TY - JOUR AU - Kim, H. S. AU - Lee, J. Y. AU - Lim, S. H. AU - Park, K. AU - Sun, J. M. AU - Ko, Y. H. PY - 2016 DA - 2016// TI - Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma JO - Cancer Res Treat VL - 48 UR - https://doi.org/10.4143/crt.2015.249 DO - 10.4143/crt.2015.249 ID - Kim2016 ER - TY - JOUR AU - Mahoney, K. M. AU - Sun, H. AU - Liao, X. AU - Hua, P. AU - Callea, M. AU - Greenfield, E. A. PY - 2015 DA - 2015// TI - PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0116 DO - 10.1158/2326-6066.CIR-15-0116 ID - Mahoney2015 ER - TY - JOUR AU - Jørgensen, J. T. PY - 2016 DA - 2016// TI - Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC JO - Expert Rev Mol Diagn VL - 16 UR - https://doi.org/10.1586/14737159.2016.1117389 DO - 10.1586/14737159.2016.1117389 ID - Jørgensen2016 ER - TY - JOUR AU - Kerr, K. M. AU - Tsao, M. S. AU - Nicholson, A. G. AU - Yatabe, Y. AU - Wistuba, I. I. AU - Hirsch, F. R. PY - 2015 DA - 2015// TI - Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000526 DO - 10.1097/JTO.0000000000000526 ID - Kerr2015 ER - TY - JOUR AU - He, X. H. AU - Xu, L. H. AU - Liu, Y. PY - 2005 DA - 2005// TI - Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain JO - Acta Pharmacol Sin VL - 26 UR - https://doi.org/10.1111/j.1745-7254.2005.00086.x DO - 10.1111/j.1745-7254.2005.00086.x ID - He2005 ER - TY - JOUR AU - Nielsen, C. AU - Ohm-Laursen, L. AU - Barington, T. AU - Husby, S. AU - Lillevang, S. T. PY - 2005 DA - 2005// TI - Alternative splice variants of the human PD-1 gene JO - Cell Immunol VL - 235 UR - https://doi.org/10.1016/j.cellimm.2005.07.007 DO - 10.1016/j.cellimm.2005.07.007 ID - Nielsen2005 ER - TY - JOUR AU - Yu, G. T. AU - Bu, L. L. AU - Huang, C. F. AU - Zhang, W. F. AU - Chen, W. J. AU - Gutkind, J. S. PY - 2015 DA - 2015// TI - PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma JO - Oncotarget VL - 6 ID - Yu2015 ER - TY - JOUR AU - Ilie, M. AU - Hofman, V. AU - Dietel, M. AU - Soria, J. C. AU - Hofman, P. PY - 2016 DA - 2016// TI - Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients JO - Virchows Arch VL - 468 UR - https://doi.org/10.1007/s00428-016-1910-4 DO - 10.1007/s00428-016-1910-4 ID - Ilie2016 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Perez-Gracia, J. L. AU - Han, J. Y. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Stewart, R. AU - Morrow, M. AU - Hammond, S. A. AU - Mulgrew, K. AU - Marcus, D. AU - Poon, E. PY - 2015 DA - 2015// TI - Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-14-0191 DO - 10.1158/2326-6066.CIR-14-0191 ID - Stewart2015 ER - TY - JOUR AU - Akbari, O. AU - Stock, P. AU - Singh, A. K. AU - Lombardi, V. AU - Lee, W. L. AU - Freeman, G. J. PY - 2010 DA - 2010// TI - PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions JO - Mucosal Immunol VL - 3 UR - https://doi.org/10.1038/mi.2009.112 DO - 10.1038/mi.2009.112 ID - Akbari2010 ER - TY - JOUR AU - Matsumoto, K. AU - Fukuyama, S. AU - Eguchi-Tsuda, M. AU - Nakano, T. AU - Matsumoto, T. AU - Matsumura, M. PY - 2008 DA - 2008// TI - B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma JO - Biochem Biophys Res Commun VL - 365 UR - https://doi.org/10.1016/j.bbrc.2007.10.156 DO - 10.1016/j.bbrc.2007.10.156 ID - Matsumoto2008 ER - TY - JOUR AU - Matsumoto, K. AU - Inoue, H. AU - Nakano, T. AU - Tsuda, M. AU - Yoshiura, Y. AU - Fukuyama, S. PY - 2004 DA - 2004// TI - B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism JO - J Immunol VL - 172 UR - https://doi.org/10.4049/jimmunol.172.4.2530 DO - 10.4049/jimmunol.172.4.2530 ID - Matsumoto2004 ER - TY - BOOK AU - Rizvi, N. A. AU - Brahmer, J. R. AU - Ou, S. -. H. I. AU - Segal, N. H. AU - Khleif, S. AU - Hwu, W. -. J. PY - 2015 DA - 2015// TI - Safety and Clinical Activity of MEDI4736, an Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody, in Patients With non-Small Cell Lung Cancer (NSCLC) PB - Poster presented at the 51st American Society of Clinical Oncology Annual Meeting CY - Chicago ID - Rizvi2015 ER - TY - BOOK AU - Segal, N. H. AU - Ou, S. -. H. I. AU - Balmanoukian, A. S. AU - Fury, M. G. AU - Massarelli, E. AU - Brahmer, J. R. PY - 2015 DA - 2015// TI - Safety and Efficacy of MEDI4736, an Anti-PD-L1 Antibody, in Patients from a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Expansion Cohort PB - Poster presented at the 51st American Society of Clinical Oncology Annual Meeting CY - Chicago ID - Segal2015 ER - TY - JOUR AU - Yang, C. Y. AU - Lin, M. W. AU - Chang, Y. L. AU - Wu, C. T. AU - Yang, P. C. PY - 2014 DA - 2014// TI - Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2014.01.018 DO - 10.1016/j.ejca.2014.01.018 ID - Yang2014 ER - TY - JOUR AU - Velcheti, V. AU - Schalper, K. A. AU - Carvajal, D. E. AU - Anagnostou, V. K. AU - Syrigos, K. N. AU - Sznol, M. PY - 2014 DA - 2014// TI - Programmed death ligand-1 expression in non-small cell lung cancer JO - Lab Invest VL - 94 UR - https://doi.org/10.1038/labinvest.2013.130 DO - 10.1038/labinvest.2013.130 ID - Velcheti2014 ER - TY - JOUR AU - Boland, J. M. AU - Kwon, E. D. AU - Harrington, S. M. AU - Wampfler, J. A. AU - Tang, H. AU - Yang, P. PY - 2013 DA - 2013// TI - Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung JO - Clin Lung Cancer VL - 14 UR - https://doi.org/10.1016/j.cllc.2012.05.006 DO - 10.1016/j.cllc.2012.05.006 ID - Boland2013 ER - TY - JOUR AU - Schmidt, L. H. AU - Kummel, A. AU - Gorlich, D. AU - Mohr, M. AU - Bröckling, S. AU - Mikesch, J. H. PY - 2015 DA - 2015// TI - PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0136023 DO - 10.1371/journal.pone.0136023 ID - Schmidt2015 ER - TY - JOUR AU - Strome, S. E. AU - Dong, H. AU - Tamura, H. AU - Voss, S. G. AU - Flies, D. B. AU - Tamada, K. PY - 2003 DA - 2003// TI - B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma JO - Cancer Res VL - 63 ID - Strome2003 ER - TY - JOUR AU - Antonia, S. J. AU - Gettinger, S. AU - Goldman, L. Q. AU - Chow, R. AU - Juergens, H. AU - Borghaei, H. PY - 2014 DA - 2014// TI - Safety and efficacy of first-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC): metastatic non-small cell lung cancer JO - Int J Rad Oncol VL - 90 UR - https://doi.org/10.1016/j.ijrobp.2014.08.207 DO - 10.1016/j.ijrobp.2014.08.207 ID - Antonia2014 ER - TY - JOUR AU - Carbognin, L. AU - Pilotto, S. AU - Milella, M. AU - Vaccaro, V. AU - Brunelli, M. AU - Calio, A. PY - 2015 DA - 2015// TI - Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0130142 DO - 10.1371/journal.pone.0130142 ID - Carbognin2015 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Gettinger, S. N. AU - Horn, L. AU - Gandhi, L. AU - Spigel, D. R. AU - Antonia, S. J. AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Garon, E. B. AU - Patnaik, A. AU - Gandhi, L. AU - Leighl, N. B. AU - Balmanoukian, A. S. PY - 2014 DA - 2014// TI - Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) JO - J Clin Oncol VL - 32 ID - Rizvi2014 ER - TY - STD TI - Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65. doi:10.1016/S1470-2045(15)70054–9. ID - ref47 ER - TY - STD TI - Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Goldman J, et al. First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. Int J Rad Oncol. 2014;90(5Suppl):S31. Abstract 165. ID - ref48 ER - TY - STD TI - Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. doi:10.1016/S0140-6736(16)00587–0. ID - ref49 ER - TY - STD TI - Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: a phase Ib trial. Eur J Cancer. 2015;51(3 Suppl):S629. Abstract 3090. ID - ref50 ER - TY - BOOK AU - Ratcliffe, M. J. AU - Sharpe, A. AU - Midha, A. AU - Barker, C. AU - Scott, M. AU - Scorer, P. PY - 2016 DA - 2016// TI - A Comparative Study of PD-L1 Diagnostic Assays and the Classification of Patients as PD-L1 Positive and PD-L1 Negative PB - Poster presented at the American Association for Cancer Research (AACR) Annual Meeting CY - New Orleans ID - Ratcliffe2016 ER - TY - JOUR AU - Phillips, T. AU - Simmons, P. AU - Inzunza, H. D. AU - Cogswell, J. AU - Novotny, J. AU - Taylor, C. PY - 2015 DA - 2015// TI - Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer JO - Appl Immunohistochem Mol Morphol VL - 23 UR - https://doi.org/10.1097/PAI.0000000000000256 DO - 10.1097/PAI.0000000000000256 ID - Phillips2015 ER - TY - JOUR AU - Miller, R. AU - Siegmund, D. PY - 1982 DA - 1982// TI - Maximally selected chi square statistics JO - Biometrics VL - 38 UR - https://doi.org/10.2307/2529881 DO - 10.2307/2529881 ID - Miller1982 ER - TY - JOUR AU - Youden, W. J. PY - 1950 DA - 1950// TI - Index for rating diagnostic tests JO - Cancer VL - 3 UR - https://doi.org/3.0.CO;2-3 DO - 3.0.CO;2-3 ID - Youden1950 ER - TY - JOUR AU - Kerr, K. M. AU - Hirsch, F. R. PY - 2016 DA - 2016// TI - Programmed death ligand 1 immunohistochemistry: friend or foe? JO - Arch Pathol Lab Med VL - 140 UR - https://doi.org/10.5858/arpa.2015-0522-SA DO - 10.5858/arpa.2015-0522-SA ID - Kerr2016 ER -